CA2255539A1 - Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma - Google Patents

Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma

Info

Publication number
CA2255539A1
CA2255539A1 CA002255539A CA2255539A CA2255539A1 CA 2255539 A1 CA2255539 A1 CA 2255539A1 CA 002255539 A CA002255539 A CA 002255539A CA 2255539 A CA2255539 A CA 2255539A CA 2255539 A1 CA2255539 A1 CA 2255539A1
Authority
CA
Canada
Prior art keywords
trauma
humans
protein products
bpi protein
therapeutic uses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002255539A
Other languages
French (fr)
Other versions
CA2255539C (en
Inventor
Patrick J. Scannon
Nancy Wedel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Corp
Original Assignee
Xoma Corporation
Patrick J. Scannon
Nancy Wedel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corporation, Patrick J. Scannon, Nancy Wedel filed Critical Xoma Corporation
Publication of CA2255539A1 publication Critical patent/CA2255539A1/en
Application granted granted Critical
Publication of CA2255539C publication Critical patent/CA2255539C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Abstract

Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered.
CA002255539A 1996-05-23 1997-05-23 Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma Expired - Fee Related CA2255539C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65229296A 1996-05-23 1996-05-23
US08/652,292 1996-05-23
PCT/US1997/008941 WO1997044056A1 (en) 1996-05-23 1997-05-23 Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma

Publications (2)

Publication Number Publication Date
CA2255539A1 true CA2255539A1 (en) 1997-11-27
CA2255539C CA2255539C (en) 2005-09-27

Family

ID=24616300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255539A Expired - Fee Related CA2255539C (en) 1996-05-23 1997-05-23 Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma

Country Status (10)

Country Link
US (2) US5945399A (en)
EP (1) EP0907372B1 (en)
JP (1) JP2000511190A (en)
CN (1) CN1155403C (en)
AT (1) ATE234111T1 (en)
AU (1) AU736096B2 (en)
CA (1) CA2255539C (en)
DE (1) DE69719754D1 (en)
NZ (1) NZ332954A (en)
WO (1) WO1997044056A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
CA2227292A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6528255B1 (en) * 1997-12-30 2003-03-04 Genencor International, Inc. Proteases from gram positive organisms
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
EP1731175B1 (en) * 1998-11-12 2009-09-30 International Manufacturing Group, Inc. Hemostatic cross-linked dextran beads useful for rapid blood coagulation and hemostatis
US6162237A (en) * 1999-04-19 2000-12-19 Chan; Winston Kam Yew Temporary intravascular stent for use in retrohepatic IVC or hepatic vein injury
CA2430588A1 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd. Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
MXPA04006438A (en) 2001-12-31 2005-06-08 Ares Lab Llc Hemostatic compositions and methods for controlling bleeding.
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
JP5361386B2 (en) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Matrix metalloproteinase 11 vaccine
CN2887006Y (en) * 2005-11-30 2007-04-04 富士康(昆山)电脑接插件有限公司 Shielding structure for electronic device
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
CN106020478B (en) * 2016-05-20 2019-09-13 青岛海信电器股份有限公司 A kind of intelligent terminal control method, device and intelligent terminal

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245013A (en) * 1985-04-30 1993-09-14 Richard Ulevitch Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides
ATE312844T1 (en) * 1987-08-11 2005-12-15 Univ New York BIOLOGICALLY ACTIVE BACTERICIDES/PERMEABILITY-INCREASING PROTEIN BREAKS
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
JPH07502642A (en) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド A novel form of liposaccharide binding protein (LBP)
WO1993023540A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
CN1163264C (en) * 1993-02-02 2004-08-25 爱克索马技术有限公司 Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
ATE165976T1 (en) * 1993-03-12 1998-05-15 Xoma Corp TREATMENT OF MYCOBACTERIAL DISEASES BY ADMINISTRATION OF BACRERIACIDAL, PERMEABILITY-INCREASE PROTEIN FRAGMENTS
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
JPH08509703A (en) * 1993-03-12 1996-10-15 ゾーマ コーポレイション Sterilization / Therapeutic use of increased permeability protein products
DK0690872T3 (en) * 1993-03-12 1999-05-10 Xoma Corp Biologically active peptides from bacterial / permeability enhancing protein functional domains and uses thereof
WO1994021280A1 (en) * 1993-03-22 1994-09-29 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
AU6942994A (en) * 1993-04-30 1994-11-21 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
AU7175694A (en) * 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
WO1995001428A1 (en) * 1993-07-02 1995-01-12 Incyte Pharmaceuticals, Inc. Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
CA2172245C (en) * 1993-09-22 2003-04-08 Jonathan Cohen Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein
CN1133634A (en) * 1993-09-22 1996-10-16 爱克斯欧玛公司 Method for quantifying BPI in body fluids
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
EP0722333B1 (en) * 1993-10-05 2004-06-16 XOMA Technology Ltd. Bpi-protein-products for depressed reticuloendothelial system function
JPH09508357A (en) * 1994-01-14 1997-08-26 ゾーマ コーポレイション Antifungal methods and materials
EP0754050B1 (en) * 1994-01-14 2002-06-26 XOMA Technology Ltd. Anti gram positive bacterial methods and materials
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
AU709738B2 (en) * 1994-09-15 1999-09-02 Xoma Corporation Anti-fungal peptides
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries

Also Published As

Publication number Publication date
CA2255539C (en) 2005-09-27
AU3369397A (en) 1997-12-09
JP2000511190A (en) 2000-08-29
CN1222859A (en) 1999-07-14
AU736096B2 (en) 2001-07-26
WO1997044056A1 (en) 1997-11-27
ATE234111T1 (en) 2003-03-15
EP0907372A1 (en) 1999-04-14
NZ332954A (en) 2000-07-28
US5756464A (en) 1998-05-26
CN1155403C (en) 2004-06-30
EP0907372B1 (en) 2003-03-12
US5945399A (en) 1999-08-31
DE69719754D1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
CA2253837A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
EP2270046A3 (en) Methods and compositions for the treatment of hemolysis-associated diseases
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
AU1679795A (en) Anti-fungal methods and materials
CA2263181A1 (en) Anti-chlamydial methods and materials
CA2268305A1 (en) Use of an h+, k+-atpase inhibitor in the treatment of nasal polyps
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
AU9395998A (en) Compositions and methods for the treatment of immune related diseases
WO1997018790A3 (en) Therapeutic and diagnostic agents for the treatment of microbial infections
EP0821969A3 (en) Medicinal Composition comprising TCF-II
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
CA2283450A1 (en) Methods for treatment of scar tissue
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
AUPN104895A0 (en) Methods of and preparations for the treatment of ailments and disorders
AU6281298A (en) Use of lofexidine in the treatment of behavioral disorders
AU3255295A (en) Hybrid molecules useful in the treatment of tumors, their preparation and use in pharmaceutical compositions
AU2742395A (en) Therapeutic or dietetic composition in the form of medicinal gel for the administration to pets
WO2000071149A3 (en) Therapeutic uses of bpi protein products in humans with otitis media with effusion
AU8760298A (en) Coup-tfi directed therapies in the treatment of disease
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
AU3117093A (en) New peptide and pseudopeptide compounds which are therapeutically active in the blood coagulation cascade, process for preparing them and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed